09th week of 2010 patent applcation highlights part 25 |
Patent application number | Title | Published |
20100055058 | USE OF STINGING CELLS/CAPSULES FOR THE DELIVERY OF ACTIVE AGENTS TO KERATINOUS SUBSTANCES - A composition of matter comprising an agent beneficial to a non-skin keratinous substance and at least one stinging capsule and methods of use are disclosed. | 2010-03-04 |
20100055059 | ASSOCIATION OF COMPOUNDS INHIBITING MELANOGENESIS AND USE THEREOF IN COSMETICS AND DERMATOLOGY - The invention relates to an association including at least : a MC1-R receptor inhibitor; a tyrosinase inhibitor derived from vitamin C; an inhibitor of the transfer of melanosomes to the keratinocytes; the invention also relates to the use thereof in cosmetics and dermatology for preparing whitening and/or bleaching depigmentation compositions. | 2010-03-04 |
20100055060 | COSMETIC COMPOSITION - The problem of the present invention is to provide a cosmetic composition, which has a moisturizing effect, and whose ability to inhibit hyaluronidase activity is high. According to the present invention, by using one or more substances selected from sulfated cellulose and a salt thereof in combination with polyhydric alcohol, the moisturizing effect of sulfated cellulose and the ability to inhibit hyaluronidase activity can be further improved, and thereby the above-described problem can be solved. In addition, the present invention can provide a cosmetic composition having excellent stability through inclusion of an electrolyte having pH buffering ability. | 2010-03-04 |
20100055061 | COSMETIC PRODUCT WITH SMOOTHING EFFECT AND RUBBERY TEXTURE WHICH TURNS INTO POWDER WHEN APPLIED AND PROCESS FOR OBTAINING THE SAME - Described herein is a cosmetic product with smoothing effect with rubber consistency which turns into powder during application, and the process to obtain it. The cosmetic product is usable as a base for smoothing and mat effect make up. | 2010-03-04 |
20100055062 | COSMETIC COMPOSITION COMPRISING A PROLINE DERIVATIVE AND/OR A SALT OF THE SAID DERIVATIVE - Cosmetic composition comprising a proline derivative and/or a salt of the said derivative The present patent application relates to a cosmetic eyelash coating composition comprising an aqueous phase, at least 1% of a wax and an emulsifying system comprising at least one proline derivative or a salt of the said derivative. | 2010-03-04 |
20100055063 | Polymeric alkoxyglyceryl dimer polyester softteners - The present invention is directed to a class of polyesters that are lightly crosslinked polyesters made by reacting alkoxyglyceryl units (linked by the reaction of their hydroxyl groups) to the carboxyl group of dimer acid. The polymers and a contribute softness, lubricity and antistatic properties when applied to hair, skin, textile fiber and paper. | 2010-03-04 |
20100055064 | BLOCK COPOLYMER, COMPOSITION COMPRISING IT AND COSMETIC TREATMENT PROCESS - The present invention relates to a linear ethylenic block copolymer comprising in each block at least one ionic hydrophilic unit, which may be different from one block to another, the said ionic hydrophilic unit being present in each block in a proportion of from 2% to 100% by weight relative to the weight of the said block. | 2010-03-04 |
20100055065 | AGENT FOR INHIBITING PRODUCTION OF HEPATITIS C VIRUS AND ITS USE - This invention provides an agent for inhibiting production of hepatitis C virus with notable anti-HCV activity and without side-effects. The agent comprises a proanthocyanidin polymer composition illustrated in the following the general formula (1), | 2010-03-04 |
20100055066 | Agent for prophylactic and/or therapeutic treatment of diabetes - According to the present invention, an agent for prophylactic and/or therapeutic treatment of diabetes comprising a substance inhibiting activity of farnesoid X receptor as an active ingredient can be provided. | 2010-03-04 |
20100055067 | PERFLUOROCARBON CONJUGATE AS A BLOOD SUBSTITUTE - There are provided disclosures relating to a conjugate of a perfluorocarbon compound and a cationic polymer wherein the conjugate is a blood substitute. | 2010-03-04 |
20100055098 | METHOD FOR TREATING MULTIPLE SCLEROSIS PATIENTS WITH ANTI-IL2R ANTIBODIES - Methods are disclosed for using anti-IL-2R antibodies for the treatment of MS patients. In certain embodiments, the patients have neutralizing antibodies to IFN-beta. | 2010-03-04 |
20100055099 | Diagnostics and Treatments for VEGF-Independent Tumors - Methods for identifying or diagnosing VEGF-independent tumors and methods for treating VEGF-independent tumors are provided. | 2010-03-04 |
20100055100 | Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples - Methods using mass spectral data analysis and a classification algorithm provide an ability to determine whether a non-small-cell lung cancer patient, head and neck squamous cell carcinoma or colorectal cancer patient has likely developed a non-responsiveness to treatment with a drug targeting an epidermal growth factor receptor pathway. As the methods of this disclosure require only simple blood samples, the methods enable a fast and non-intrusive way of measuring when drugs targeting the EGFR pathway cease to be effective in certain patients. This discovery represents the first known example of true personalized selection of these types of cancer patients for treatment using these classes of drugs not only initially, but during the course of treatment. | 2010-03-04 |
20100055101 | CYTOKINE RECEPTOR ZCYTOR17 MULTIMERS - Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto. | 2010-03-04 |
20100055102 | COMPOSITIONS OF PD-1 ANTAGONISTS AND METHODS OF USE - Methods of treating cancer and infectious diseases utilizing a treatment regimen comprising administering a compound that reduces inhibitory signal transduction in T cells, in combination with a potentiating agent, such as cyclophosphamide, to produce potent T cell mediated responses, are described. Compositions comprising the PD-1 antagonists and potentiating agents useful in the methods of the invention are also disclosed. | 2010-03-04 |
20100055103 | CROSS-REACTIVE AND BISPECIFIC ANTI-IL-17A/F ANTIBODIES - The present invention relates generally to antibodies cross-reactive with IL-17A and IL-17F, and bispecific anti-IL-17A/F and their uses. | 2010-03-04 |
20100055104 | THERAPEUTIC COMPOSITION COMPRISING AN INHIBITOR OF AN HSP 90 PROTEIN - Use of an inhibitor of an hsp 90 protein for the manufacture of a medicament for the treatment or prophylaxis of a condition involving raised levels of TNFα and/or IL-6. | 2010-03-04 |
20100055105 | Novel Isolated And Purified Strains Of Chikungunya Virus And Polynucleotides And Polypetide Sequences, Diagnostic And Immunogenical Uses Thereof - The present invention concerns wild-strains of Chikungunya virus isolated from patients exhibiting severe forms of infection and stemming from a human arbovirosis epidemy. The present invention also concerns polypeptide sequences and fragment thereof derived from their genome, the polynucleotide encoding same and their use as diagnostic products, as vaccine and/or as immunogenic compositions. | 2010-03-04 |
20100055106 | METHODS FOR REGULATING COMPLEMENT CASCADE PROTEINS USING ASTROVIRUS COAT PROTEIN AND DERIVATIVES THEREOF - The present invention provides a method for modulating the complement cascade by depleting the plasma of the functional activity of complement proteins and thereby reducing or eliminating complement-mediated cell lysis. The invention provides a method for the therapeutic use of coat proteins and derivatives thereof from the Astroviradae family of viruses in the treatment of complement-mediated cell lysis and peptide mediators of inflammation. The invention provides a method for the therapeutic use of coat proteins and derivatives thereof from the Astroviradae family of viruses in the treatment of complement-mediated diseases. Methods are described herein where complement cascade, triggered by either the classical or alternative complement pathways, is prevented from effecting cell lysis and inflammation due to inhibition or depletion of one or more complement components in the serum following administration of astrovirus coat proteins or derivatives. | 2010-03-04 |
20100055107 | METHODS FOR PREVENTING HEMATOLOGICAL MALIGNANCIES AND GRAFT VERSUS HOST DISEASE BY ANTI-CD3 PRECONDITIONING - Graft versus host disease (GVHD) may be prevented, while preserving a beneficial by graft versus leukemia (GVL) effect, in a subject receiving an allogeneic hematopoietic cell transplant by preconditioning the subject with a CD3 modulator, such as an agonistic anti-CD3 antibody. More than one CD3 modulator may be administered at one time. This method may be performed alone or in conjunction with irradiation of the subject. The use of anti-CD3 to precondition a subject to reduce tissue release of chemokines and prevents tissue dendritic cell migration to draining lymph nodes is also provided. Anti-CD3 preconditioning may also be used to modulate host dendritic cells before hematopoietic cell transplantation. | 2010-03-04 |
20100055108 | DRUG FOR TREATING GASTRIC CANCER - The invention relates to the use of at least one interleukin-17 inhibitor and/or of at least one IL-17 receptor inhibitor, for the manufacture of a medicament for inhibiting, preventing or treating gastric cancer. | 2010-03-04 |
20100055109 | POST-TRANSLATIONALLY MODIFIED NEUROTROPHINS - The present invention describes that neurotrophins undergo post-translational modifications, and that these post-translational modifications mediate the pro-apoptotic and/or pro-neurite activity of neurotrophins. These post-translational modifications notably include nitration and the formation of conformationally-different dimers, as well as of abnormal oligomers, such as tetramers and octamers. The invention further relates to compounds that compete with such modified neurotrophins, as well as to compounds that binds to said modified neurotrophins. The invention thus provides useful agents for the treatment of the conditions or diseases involving a chronic pain and/or neuron loss. | 2010-03-04 |
20100055110 | IL-1BETA BINDING ANTIBODIES AND FRAGMENTS THEREOF - An IL-1β binding antibody or IL-1β binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an affinity matured IL-1β binding polypeptide. IL-1β binding antibodies or IL-1β binding fragments thereof are provided which have desirable affinity and potency. | 2010-03-04 |
20100055111 | INDOLEAMINE 2,3-DIOXYGENASE, PD-1/PD-L PATHWAYS, AND CTLA4 PATHWAYS IN THE ACTIVATION OF REGULATORY T CELLS - The present invention includes methods of enhancing immune responses by administering an inhibitor of indoleamine-2,3-dioxygenase (IDO) along with one or more inhibitors of the PD-1/PD-L pathway and/or one or more inhibitors of the CTLA4 pathway. | 2010-03-04 |
20100055112 | Enterococcus faecalis and/or Enterococcus faecium antigen - The present invention generally relates to the field of detecting and preventing infectious diseases caused by | 2010-03-04 |
20100055113 | CELLULAR RECEPTOR FOR ANTIPROLIFERATIVE FACTOR - The present invention concerns the receptor for antiproliferative factor (APF) from bladder epithelial cells. In particular, there are compositions and methods for modulating APF, APF receptor, and/or the binding of APF to APF receptor. Agents that interfere with the binding of APF to its receptor or agents that enhance the binding of APF to its receptor are contemplated. In specific aspects, certain compositions are employed for a therapeutic purpose, such as interstitial cystitis or cancer, for example. | 2010-03-04 |
20100055114 | USE OF INTEGRIN ALPHA 10 BINDING ANTIBODY TO MODULATE EXTRACELLULAR MATRIX (CARTILAGE) TURNOVER - The present invention relates to a novel use of alpha10, or a heterodimer thereof, for affecting cartilage extracellular matrix (ECM) turnover. Further, it relates to the use of a binding entity binding specifically to alpha10, or a heterodimer thereof, in the preparation of a medicament for treating a condition affecting ECM, such as rheumatoid arthritis and osteoarthritis. In particular, the invention relates to a method of treating an individual with a condition affecting ECM turnover, comprising administering to the individual an effective amount of a binding agent entity binding specifically to alpha10, or a heterodimer thereof. | 2010-03-04 |
20100055115 | COMPOSITIONS AND METHODS FOR STEM CELL DELIVERY - This invention provides compositions of matter, articles of manufacture and methods for delivering and/or affixing a stem cell to a target tissue. This invention also provides related nucleic acids, vectors, cell, methods of production, and kits. | 2010-03-04 |
20100055116 | Methods and Compositions for Targeting c-Rel - The present invention relates to compositions and methods for targeting c-Rel. In particular, the present invention provides compositions and methods for treating cancers, inflammatory diseases, autoimmune diseases, and transplant rejection by inhibiting c-Rel activity and for regulating c-Rel for research and drug screening applications. | 2010-03-04 |
20100055117 | ALLORESTRICTED PEPTIDE-SPECIFIC T CELLS - The present invention is directed to a T cell receptor (TCR) recognizing antigenic peptides derived from tumor-associated antigen FMNL1/KW13 and being capable of inducing peptide specific killing of a target cell. The present invention is further directed to one antigenic peptides derived from tumor-associated antigen FMNL1/KW13, to an antigen specific T cell, comprising said TCR, to a nucleic acid coding for said TCR and to the use of the antigen specific T cells for the manufacture of a medicament for the treatment of malignancies characterized by overexpression of FMNL1/KW13. | 2010-03-04 |
20100055138 | METHODS AND TOPICAL FORMULATIONS COMPRISING COLLOIDAL METAL FOR TREATING OR PREVENTING SKIN CONDITIONS - In preferred embodiments, the present invention relates to compositions comprising colloidal metals and/or metals for the treatment and prevention of skin conditions and/or diseases. More specifically, the disclosed metal containing compositions are useful as antioxidants, anti-aging agents, anti-wrinkle agents, anti-peroxidation agents, antimicrobial agents, anti-inflammatory agents, pain-relieving agents, wound recovery agents, sun-screens, sunblocks, and integument and skin-supporting agents when applied to the skin/integument, or administered generally to an animal or human body. | 2010-03-04 |
20100055139 | Compositions Comprising Solid Particles Encapsulated In A Cross-Linked Silicone Matrix, And Methods Of Making The Same - The present invention relates to topical compositions containing solid particles that are stabilized via encapsulation into a cross-linked silicone matrix. The solid particles are preferably formed of a metal oxide, such as zinc oxide or titanium dioxide, and the cross-linked silicone matrix is preferably formed by cross-linking a silicone having branched reactive alkoxyl moieties in the presence of a stannous carboxylate cross-linking agent. The stabilized particles of the present invention can readily be used either alone or in combination with other skin care actives to form topical compositions with improved stability and performance. | 2010-03-04 |
20100055140 | PRESSED POWDER COSMETIC COMPOSITION COMPRISING FLAKY GLASS - The present invention is directed to a pressed powder cosmetic composition, comprising by weight: (a) from about 75% to about 98% of a powder component, the powder component comprising a cosmetic grade flaky glass constituted of components comprising by weight at least 52% silicone dioxide and no more than 5% alkali metal oxide, and wherein the cosmetic grade flaky glass has an average thickness of 0.1-1.0 μm, an average particle diameter of 1-100 μm, and an aspect ratio, obtained by dividing the average particle diameter by the average thickness, of 10 or higher; (b) from about 1% to about 24% of a powder binder, the powder binder comprising sodium stearyl fumarate; and (c) from about 1% to about 25% of a liquid binder. | 2010-03-04 |
20100055141 | PROCESS FOR THE PREPARATION OF COLOURED PARTICULATES - The present invention provides a process of preparing stained particulates of glass, partially crystalline glass or glass-like amorphous inorganic materials, the process comprising staining particulates of glass, partially crystalline glass or glass-like amorphous inorganic materials that have no dimension greater than 2000 μm. | 2010-03-04 |
20100055142 | Carrier Neutralization/Modification in Antimicrobial Compositions, Articles and Methods - A method of treating a substrate having a charge bias with at least one antimicrobial agent to modify the release properties of the antimicrobial agent with respect to the substrate, the method includes eliminating, mitigating, or modifying the charge bias of the substrate by applying at least one first agent to the substrate, and applying the at least one antimicrobial agent to the substrate. Related articles are also described. | 2010-03-04 |
20100055143 | POWDERY PESTICIDAL COMPOSITION - Disclosed is a powdery pesticidal composition which comprises a mixture of a coated pesticide comprising a powdery pesticide coated with a thermosetting resin and having a volume median diameter of 10 to 150 μm and a calcium carbonate micropowder having a bulk density of 0.6 g/ml or less, wherein the weight-based ratio of the coated pesticide to the calcium carbonate micropowder is 100:1 to 100:30. The powdery pesticidal composition has good fluidability. | 2010-03-04 |
20100055144 | High aspect ratio template and method for producing same - Millimeter to nano-scale structures manufactured using a multi-component polymer fiber matrix are disclosed. The use of dissimilar polymers allows the selective dissolution of the polymers at various stages of the manufacturing process. In one application, biocompatible matrixes may be formed with long pore length and small pore size. The manufacturing process begins with a first polymer fiber arranged in a matrix formed by a second polymer fiber. End caps may be attached to provide structural support and the polymer fiber matrix selectively dissolved away leaving only the long polymer fibers. These may be exposed to another product, such as a biocompatible gel to form a biocompatible matrix. The polymer fibers may then be selectively dissolved leaving only a biocompatible gel scaffold with the pores formed by the dissolved polymer fibers. | 2010-03-04 |
20100055145 | STENT COATINGS FOR REDUCING LATE STENT THROMBOSIS - Devices and methods relate to drug-eluting stents and coatings, thereof, for reduced late stent thrombosis are described. | 2010-03-04 |
20100055146 | CYCLIC ANGIOTENSIN ANALOGS - The invention relates to analogs of angiotensins, in particular to cyclised analogs having Ang(1-8) agonistic or antagonistic activity and to cyclised Ang(1-7) analogs with agonistic or antagonistic activity and displaying improved proteolytic resistance compared to their linear counterparts. Provided is a cyclic angiotensin peptide analog comprising a thioether-bridge linkage between the amino acids corresponding to positions Tyr | 2010-03-04 |
20100055147 | ANGIOTENSIN (1-7) ELUTING STENT - Medical devices with polymer coatings designed to control the release of bioactive agents in combination with angiotensin-(1-7) receptor agonists from medical devices are disclosed. Methods for treating or inhibiting post-stent implantation restenosis as well as improving vascular endothelial function in patients are also provided. | 2010-03-04 |
20100055148 | Biological artificial nerve guide and method of making - A biological nerve guide for implantation into a human body is made by providing a natural animal tissue membrane, crosslinking and fixing the membrane, minimizing the antigens from the membrane, tanning the membrane, coupling an active layer to an inner surface of the membrane, cutting the membrane into a desired shape and size, positioning the cut membrane onto a rod-shaped mold so that the cut membrane assumes a cylindrical configuration, and attaching a spiral support to the outer surface of the cut membrane. | 2010-03-04 |
20100055149 | RE-ROLLABLE WRAPPING IMPLANT - A re-rollable membrane for wrapping around and protecting a cylindrical tissue having an injury site. The membrane includes a sheet of a porous matrix formed of cross-linked biopolymeric fibers. In one implementation, the sheet can be spirally rolled so that at least one portion overlaps another portion of the sheet and, upon absorption of a fluid, the overlapping portions adhere to each other closely so as to exclude penetration of cells. In another implementation, the sheet can be helically rolled to form a helix having a pitch of 2 mm to 40 mm and an inner diameter of 1 mm to 50 mm. Also disclosed are methods for making and using such re-rollable membranes. | 2010-03-04 |
20100055150 | METHOD AND COMPOSITION FOR TREATMENT OF SKELETAL DYSPLASIAS - The present invention relates to a method for the treatment of skeletal dysplasia by administering to a patient a composition comprising a therapeutically effective amount of at least one C-type natriuretic peptide (CNP). | 2010-03-04 |
20100055151 | MEDICAL DEVICES HAVING COATINGS FOR THERAPEUTIC AGENT DELIVERY - According to an aspect of the invention, implantable and insertable medical devices are provided that include (a) a substrate, (b) a porous layer comprising interconnected pores disposed over the substrate, (c) at least one first therapeutic agent disposed within and/or beneath the porous layer, (d) a composite layer disposed over the porous layer that includes (i) at least one therapeutic agent eluting region containing at least one second therapeutic agent and at least one matrix material and (ii) at least one bioerodible region containing at least one bioerodible material that extends from the surface of the composite layer to the porous layer. | 2010-03-04 |
20100055152 | ANTIHISTAMINE AND ANTIHISTAMINE-LIKE NASAL APPLICATION, PRODUCTS, AND METHOD - A method of and product for reducing the undesirable effects of allergic rhinitis by applying a formulation to a person's nasal region or nostrils. The formulation creates a barrier that prevents airborne allergens from contacting nasal mucous membranes, and at the same time, electrostatically repels or attracts and captures the particulate allergens, and changes their shapes so as to mitigate the effects of allergic rhinitis. The formulation may be made more effective by the addition of an anti-histamine compound. | 2010-03-04 |
20100055153 | Multipurpose hydrogel compositions and products - Disclosed are sterile hydrogel compositions comprising polyvinyl alcohol (“PVA”), polyvinyl pyrrolidone (“PVP”), and a polysaccharide, wherein the combined amount of PVA and PVP present in the hydrogel compositions is from about 2% to about 12% weight by volume, based on the total volume of the composition, and wherein the hydrogel compositions has a gel fraction greater than or equal to 97%. Sterile hydrogel products including such sterile hydrogel compositions, and methods of making such sterile hydrogel compositions and sterile hydrogel products. | 2010-03-04 |
20100055154 | COAXIAL ELECTROSPUN FIBERS AND STRUCTURES AND METHODS OF FORMING THE SAME - Nanofibers and microfibers having a core and a polymer shell surrounding the core are provided. The shell includes a plurality of channels that extend from an outer shell surface to the core, and one or more agents, such as pharmacological materials, proteins, viruses, plasmid DNA, bacterial cells, drug-loaded nanoparticles, are encapsulated within the core. The one or more agents discharge from the core through the channels at a controlled rate. The channels are formed by porogen material within the polymer shell. | 2010-03-04 |
20100055155 | SOLID DEODORIZER FOR OSTOMY POUCHES - A solid deodorizer ( | 2010-03-04 |
20100055156 | COMPOSITION FOR THE TOPICAL TRANSMISSION OF ACTIVE INGREDIENTS INTO THE HUMAN OR ANIMAL BODY - Improved composition for transmission into the human or animal body of pharmaceutical, cosmetic or nutritional active ingredients, said transmission occurring by topical application on the skin and/or mucous membrane of the body. | 2010-03-04 |
20100055157 | SILVER BASED ANTIMICROBIAL COMPOSITIONS AND ARTICLES - Antimicrobial articles, including cohesive, adhesive, and pressure-sensitive adhesive articles, comprising a substrate and a silver compound, and methods of making antimicrobial articles are described. | 2010-03-04 |
20100055158 | Environmentally Activated Compositions, Articles and Methods - An article includes a film layer; at least one layer of adhesive on at least one side of the film layer; a patch or strip comprising at least one antimicrobial agent, the patch or strip disposed on the same side of the film layer as the at least one layer of adhesive; and a relatively non-flexible sheet releasably attached to the side of the film layer opposite to the patch or strip. Alternatively, an article includes a film layer; a collagen layer; and a biodegradable hydrogel layer comprising PHMB; wherein the biodegradable hydrogel layer comprising PHMB is disposed between the film layer and the collagen layer | 2010-03-04 |
20100055159 | PERCUTANEOUS PREPARATIONS - A bisphosphonic acid derivative-containing percutaneous preparation of an excellent percutaneous permeability, comprising a bisphosphonic acid derivative such as incadronic acid, minodronic acid, etc., or pharmaceutically acceptable salts thereof, a solubilizing agent for the derivative or pharmaceutically acceptable salts thereof, and an amphiphilic solubilizing auxiliary agent, which may optionally contain a suspension-type base such as a polyvalent alcohol, a higher fatty acid ester, a liquid hydrocarbon or a vegetable oil, etc. This preparation has an excellent percutaneous permeability, reduces burdens on the patient, does not deteriorate the patient's compliance even in the administration over a prolonged period of time and can achieve the therapeutic effects in a short period of time. | 2010-03-04 |
20100055160 | ANALGESIC ANTI-INFLAMMATORY PATCHES FOR TOPICAL USE - The invention provides an analgesic anti-inflammatory patch of a hydrophobic type for topical application containing, in a Pressure Sensitive Adhesive(PSA), diclofenac sodium, pyrrolidone or a derivative thereof, a polyhydric alcohol fatty acid ester, and an organic acid. The patch exerts the following effects: | 2010-03-04 |
20100055161 | HYDROGEL FACE MASK FOR DELIVERING SKIN CARE AGENTS - Skin care can be provided by the skin care devices and compositions described herein. Such a skin care device can be configured to include a biocompatible hydrogel layer including one or more treatment agents, and an associated backing layer associated with the hydrogel layer. | 2010-03-04 |
20100055162 | ADHESIVE PATCH - An adhesive patch having a support | 2010-03-04 |
20100055163 | FORMULATION OF NATURAL TRITERPENES AND BIOPHENOLS OBTAINED FROM THE GENUS OLEA IN LIPOSOMES - The present invention relates to compositions of natural biophenols and, optionally, of natural biophenols and triterpenes obtained from the genus | 2010-03-04 |
20100055164 | SYNTHETIC LUNG SURFACTANT AND USE THEREOF - The present invention relates to synthetic lung surfactant compositions that contain one or more of phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, and surface active proteins or peptides, more preferably a combination of at least two or all three of these materials. Novel phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, and surface active peptides are also disclosed herein. Uses of the surfactant compositions of the present invention to treat endogenous surfactant dysfunctional or deficient lung tissue, to prepare synthetic peptides for use in the surfactant compositions, and to deliver therapeutic agents are also disclosed. | 2010-03-04 |
20100055165 | LIPOSOMAL GEL PHTHALOCYANINE PREPARATION FOR PHOTODYNAMIC THERAPY OF TUMORS AND ITS MANUFACTURING - Liposomal gel hydrophobic phthalocyanine (FCH) preparation for photodynamic therapy of tumors and other diseases is composed of lecithin liposomes or liposomes on the basis of other lipids, with incorporated curing drug, which can be chosen either from a group including hydrophobic hydroxyaluminum phthalocyanine, hydrophobic aluminum phthalocyanine, hydrophobic zinc phthalocyanine, hydrophobic silicone phthalocyanine, or organic silicone phthalocyanine, or hydrophobic phthalocyanine without the core metal; while resulting liposomes are mixed in ratios of 10:1 to 1:10 with a translucent gel, advantageously on the basis of carboxymethylcellulose. The added curing drug can be coated by glucose or other saccharides, by polyethylenglycol or other usable polymers, as lecithin or other lipids, or by sodium chloride or other salts usable in pharmacology. Liposomal gel hydrophobic phthalocyanine (FCH) preparation is manufactured on the following schema: Lecithin or other lipid of a pharmacological purity at concentration between 10 to 40 mg per ml of sterile isotonic solution is fluidised on a microfluidizer in particular chamber to the final particle size smaller than 1000 nm, in temperature higher than 0° C. and a pressure at 500 to 2000 Bar; then while stirring the curing drug or the treated curing drug is added in the ratio of 5:1 to 0.1:1 in relation to the lecithin or other lipid; the resulting suspension is again fludized on a microfludizer in particular smaller chamber to the final particle size smaller than 500 nanometer, with pressure at least 1000 to 2000 Bar, in temperature higher than 0° C.; the resulting suspension is then mixed with a translucent gel in ratios of 10:1 to 1:10; Alternatively, first lecithin or other lipid of a pharmacological purity at concentration between 10 to 40 mg per ml of sterile isotonic solution is microfludized on a microfluidizer in particular chamber to the final particle size smaller than 1000 nm, a pressure at least 1000 to 2000 Bar and temperature higher than 0° C.; Afterwards, in parallel the curing drug or the treated curing drug is separately microfluidized in amounts corresponding to the ratio of 5:1 to 0.1:1 in relation to the lecithin or other lipid in an equal volume of fluid, advantageously on the basis of sterile isotonic solution to the final particle size smaller than 1000 nanometer, and with pressure at 1000 to 2000 Bar; Afterwards both microfludized components are mixed together and again microfludized on a microfludizer in particular chamber with a pressure at 1000 to 2000 Bar and temperature higher than 0° C. to the final particle size maximum of 500 nanometer, the resulting suspension is fluidised on a microfluidizer in a particular smaller chamber with a pressure at least 1000 to 2000 Bar and temperature higher than 0° C. to the final particle size smaller then 500 nm, the resulting suspension is then mixed with a translucent gel in ratios of 10:1 to 1:10; Alternatively, Lecithin or other lipid in the pharmacological purity at the concentration of 10 to 40 mg per milliliter of sterile isotonic solution is first treated by extrusion across the filters with a size 10 to 500 nm together with the curing drug or the treated curing drug in the ratio of 5:1 to 0.1:1 related to the lecithin or other lipid; and the resulting suspension is again fluidised on a microfluidizer in a particular chamber with a pressure at least 1000 to 2000 Bar and temperature higher than 0° C. to the final particle size smaller then 500 nm, with a pressure at least 1000 to 2000 Bar and temperature higher than 0° C., the resulting suspension is mixed with a translucent pharmaceutical gel in a ratio of 10:1 to 1:10. | 2010-03-04 |
20100055166 | NOVEL METHOD AND COMPOSITIONS - The present invention relates to, inter alia, a method of raising an immune response against a pathogen which comprises administering (i) one or more first immunogenic polypeptides derived from said pathogen; (ii) one or more adenoviral vectors comprising one or more heterologous polynucleotides encoding one or more second immunogenic polypeptides derived from said pathogen; and (iii) an adjuvant; wherein the one or more first immunogenic polypeptides, the one or more adenoviral vectors and the adjuvant are administered concomitantly. The invention also relates to vaccines, pharmaceutical compositions, kits and uses employing said polypeptides, adenoviral vectors and adjuvants. | 2010-03-04 |
20100055167 | STEM CELL DELIVERY OF ANTI-NEOPLASTIC MEDICINE - The present disclosure provides a modified stem cell comprising a stem cell and at least one controlled-release vehicle, wherein the at least one controlled-release vehicle includes at least one anti-neoplastic agent and at least one targeting moiety, and wherein the modified stem cell is characterized by an ability to target one or more glioma cells. The disclosure also provides pharmaceutical compositions and methods of treating a glioma by administering a therapeutically effective amount of the modified stem cells. | 2010-03-04 |
20100055178 | ENTERIC-COATED CREATINE COMPOSITIONS AND METHODS OF USE THEREOF - Compositions and methods are provided for supplementing dietary creatine and facilitating absorption of creatine, comprising an enteric-coated creatine pharmaceutical formulation that may be provided as a tablet, capsules, pellet, and microbead in the form of creatine monohydrate, creatine phosphate, creatine cytrate, creatine pyruvate, or creatine ethyl ester. | 2010-03-04 |
20100055179 | Composition of and Method for Preparing Orally Disintegrating Tablets Containing a High Dose of Pharmaceutically Active Ingredients - The present invention is directed to improved compositions and methods for preparing orally disintegrating tablets (ODTs). In one aspect of the present invention, the ODT further contains at least one active pharmaceutical ingredient (API). In another aspect of the present invention, the ODT contains a high load of at least one API. Specifically, the ODTs described in this invention containing a high load of API can accommodate up to about 70% w/w of active pharmaceutical ingredient in a unit dosage, while exhibiting the desirable attributes of fast disintegration time, acceptable hardness and friability for push through blister and bottle packages, and acceptable mouth feel. | 2010-03-04 |
20100055180 | Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof - An improved excipient comprising substantially homogeneous particles of a compressible, high functionality granular microcrystalline cellulose based excipient is provided. The improved excipient comprises microcrystalline cellulose and a binder, and optionally a disintegrant, and is formed by spraying a homogeneous slurry of the components. The excipient provides enhanced flowability/good flow properties, excellent/high compactibility, and increased API loading and blendability as compared to the individual components, and as compared to conventional excipients formed from the same materials. The improved excipient has strong intraparticle bonding bridges between the components, resulting in a unique structural morphology including significant open structures or hollow pores. The presence of these pores provides a surface roughness that is the ideal environment for improved blending with an API. | 2010-03-04 |
20100055181 | CONTROLLED RELEASE DOSAGE FORMS OF ZOLPIDEM - A controlled release dosage forms comprising zolpidem or a salt thereof to release zolpidem to induce rapid onset of sleep, and continue to release zolpidem in a controlled manner to maintain effective plasma concentrations over an extended period of time to improve sleep maintenance. The pharmaceutical controlled-release dosage form of zolpidem or a salt thereof having a dissolution profile when measured in a type I or II dissolution apparatus according to the U.S. Pharmacopoeia in 0.01M hydrochloric acid buffer at 37° C., such that less than 40% is released at the end of 30 minutes. | 2010-03-04 |
20100055182 | USE OF GUANIDINOACETIC ACID (SALTS) COMBINATION WITH BETAINE AND/OR CHOLINE TO PRODUCED AN AGENT THAT IS BENEFICIAL TO HEALTH - The use of guanidinoacetic acid and/or salts thereof in combination with choline and/or betaine to produce an agent for improving brain function, bone growth and the mineralization of bones, for improving cartilage growth, for alleviating aging processes, for strengthening the immune system, as an antioxidative and neuroprotective agent, for lowering the cholesterol and triglyceride value, for preventing inflammatory processes and for lowering the blood sugar level in humans and vertebrates is described. | 2010-03-04 |
20100055183 | TRIMEPRAZINE AND ETHOPROPAZINE DERIVATIVES FOR PROMOTING BONE GROWTH - The present invention provides a method of promoting bone growth in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I. The present invention also provides methods for the treatment of renal disease and cancer. | 2010-03-04 |
20100055184 | HYDROGELS FOR VOCAL CORD AND SOFT TISSUE AUGMENTATION AND REPAIR - The present invention provides hydrogels and compositions thereof for vocal cord repair or augmentation, as well as other soft tissue repair or augmentation (e.g., bladder neck augmentation, dermal fillers, breast implants, intervertebral disks, muscle-mass). The hydrogels or compositions thereof are injected into the superficial lamina propria or phonatory epithelium to restore the phonatory mucosa of the vocal cords, thereby restoring a patient's voice. In particular, it has been discovered that hydrogels with an elastic shear modulus of approximately 25 Pa are useful in restoring the pliability of the phonatory mucosa. The invention also provides methods of preparing and using the inventive hydrogels. | 2010-03-04 |
20100055185 | COMPOSITION AND METHOD FOR TREATING HEMORRHOIDS AND/OR ANORECTAL DISORDERS - The invention provides an oil-in-water emulsion useful in the treatment of anorectal disorders comprising a local anesthetic, vasoconstrictor, glycerin and water, and method of preparation of the emulsion and a method for treating hemorrhoids using the composition of the invention. | 2010-03-04 |
20100055186 | PHOTOCROSSLINKABLE OLIGO(POLY (ETHYLENE GLYCOL) FUMARATE) HYDROGELS FOR CELL AND DRUG DELIVERY - The invention provides photocrosslinkable, injectable, biodegradable oligo(poly(ethylene glycol) fumarate) (OPF) hydrogels made from the photopolymerization of an OPF macromer with UV light and a photoinitiator. Hydrogels with varying mechanical properties and water content can be made with changes in macromer and crosslinking agent concentration in a precursor solution. The biodegradable OPF hydrogels can be injected as a fluid into a bodily defect of any shape, may incorporate various therapeutic agents, e.g., cells and/or growth factors, and may be implanted via minimally invasive arthroscopic techniques. | 2010-03-04 |
20100055187 | NANOVITAMIN SYNTHESIS - Stable nanoparticulate vitamin compositions are prepared from agglomerated or larger sized vitamin particles of at least one vitamin compound by breaking down and/or solubilizing the agglomerated or larger sized vitamin particles and associating the particles with a surface modifying agent. | 2010-03-04 |
20100055188 | NANO-VALVES FOR SMALL-MOLECULE DRUG DELIVERY - A system for drug delivery including a plurality of molecular-valves that are responsive to an exterior stimulus so as to selectively open in response to the stimulus. A quantity of a drug is initially contained within the molecular-valves. The molecular-valves are associated with the surface (e.g., both the exterior surface, as well as within the internal pore structure) of the substrate. Upon exposure to a selected stimulus, the molecular-valves open, resulting in release of the drug molecules. | 2010-03-04 |
20100055189 | Nanoparticles for immunotherapy - Nanoparticles that activate complement in the absence of biological molecules are described. The nanoparticles are shown to specifically target antigen presenting cells in specifically in lymph nodes, without the use of a biological molecule for targeting. These particles are useful vehicles for delivering immunotherapeutics. Surface chemistries and chemical formulations for the nanoparticles are described. | 2010-03-04 |
20100055190 | Sterol-Containing Compositions - The invention relates to a powder formulation containing sterol in the form of a super-cooled melt from sterols and sterol esters, provided that the sterol ester content is at least 30 wt % in relation to the content of the powder. The introduced sterol ester is a fatty acid ester having a chain length of 2 to 24, preferably 8 to 12 carbon atoms. As the sterol preparations are wettable and melt easily without the use of complex equipment, they can easily be incorporated into food, and produce, in particular, good organoleptic and sensory properties, in particular, in drinks. | 2010-03-04 |
20100055191 | POWDER COMPOSITION, METHOD FOR PRODUCING THE SAME, AND FOOD COMPOSITION, COSMETIC COMPOSITION AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME - A powder composition of a functional oil material is obtained by drying an emulsion composition comprising at least one functional oil component and (i) at least one water-soluble encapsulating agent selected from saccharide containing at least two sugar units including a fructose unit or (ii) at least one water-soluble encapsulating agent selected from saccharides containing at least one galactose unit and one fructose unit. Food compositions, cosmetic compositions and pharmaceutical compositions are provided which contain the powder composition described above. | 2010-03-04 |
20100055192 | MICRONIZED PARTICLES OF LOW-DOSAGE STRENGTH ACTIVE AGENTS FOR POWDER FORMULATIONS FOR INHALATION - Micronized particles of a low-dosage strength active ingredient, to be used in dry powder formulations for inhalation, with particular properties can easily and homogenously disperse in a dry powder formulation to be administered by means of a dry powder inhaler device. | 2010-03-04 |
20100055193 | Stable powder formulation containing an anticholinergic agent - The invention relates to a spray-dried powder formulation comprising particles that contain the following components i) to iii): i) anticholinergic agents, in particular at least one compound of formula 1, in which X | 2010-03-04 |
20100055194 | PHARMACEUTICAL FORMULATIONS CONTAINING MICROPARTICLES OR NANOPARTICLES OF A DELIVERY AGENT - This invention relates to microparticles and/or nanoparticles containing a delivery agent and/or an active agent. This invention also relates to pharmaceutical formulations and solid dosage forms, including controlled release solid dosage forms of active agent and a delivery agent. | 2010-03-04 |
20100055195 | BIODEGRADABLE BMP NANOFIBER AND USES THEREOF - Described herein are compositions and methods for treating bone disorders. The compositions and methods relate to a nanofiber comprising one or more of one or more bone morphogenetic proteins, or one or more bone morphogenetic protein fragments bound to the nanofiber. | 2010-03-04 |
20100055196 | SANITIZING COMPOSITION - A sanitizing composition capable of destroying pathogens present at a locus and/or of removing biofilm present at a locus (for example MRSA or | 2010-03-04 |
20100055197 | LONG-TERM ENTERAL FEED FOR MAINTENANCE - The present invention provides methods and compositions for providing long-term tube-fed nutrition. More specifically, the present invention provides methods and compositions for providing long-term tube-fed maintenance to a patient. | 2010-03-04 |
20100055208 | Insecticidal Compositions and Uses Thereof - The present invention provides compositions and methods for controlling plant pests. In particular, the present invention provides plant extracts with insecticidal activity. | 2010-03-04 |
20100055209 | Standardized Extract And Its Use In The Manufacture Of A Medicament - The present invention refers to a medicament which activates gastrointestinal movement. The medicament consists essentially of Cucurbitacin D and one or more substances form the group including Cucurbitacin A, Cucurbitacin B, Cucurbitacin E, Isocucurbitacin B and Isocucurbitacin D. The medicament is made from an extract obtained from Muskmelon Base, the fruit stem of | 2010-03-04 |
20100055210 | COSMETIC COMPOSITION FOR PROTECTING SKIN AGAINST UV LIGHT AND WRINKLE IMPROVEMENT CONTAINING THE EXTRACT OF MAGNOLIA SIEBOLDII FLOWER EXTRACTS - Disclosed herein is a cosmetic composition for preventing photoaging, containing an extract of | 2010-03-04 |
20100055211 | PROCESS FOR PRODUCING REFINED NUTRACEUTIC EXTRACTS FROM ARTICHOKE WASTE AND FROM OTHER PLANTS OF THE CYNARA GENUS - Process for fractioning and refining natural products obtainable from waste vegetal material and particularly from artichoke ( | 2010-03-04 |
20100055212 | COSMETIC COMPOSITION COMPRISING TISSUE CULTURED PANAX GINSENG C.A. MEYERADVENTITIOUS ROOT ITSELF AND A PREPARING METHOD THEREOF - The present invention relates to a cosmetic composition comprising tissue-cultured adventitious roots itself of ginseng, and to a preparing method thereof. The cosmetic composition of the present invention is characterized in that effective ingredients are dip-extracted from the tissue cultured adventitious roots of a ginseng contained in the composition, without any additional process for preparing an extract of the tissue-cultured adventitious roots of a ginseng. In the cosmetic composition of the present invention, the effective ingredients are naturally and continuously dip-extracted from the tissue-cultured adventitious roots itself of a ginseng and maintained, and also allows a user to recognize visually the presence of the adventitious roots of a ginseng, thereby giving trust of the presence of the effective ingredient to the user, and improving user's satisfaction through its natural flavor. Further, the preparing method for the cosmetic composition is a simple and inexpensive process without any additional step, such as extraction, isolation and purification, and further has an advantage that an effective ingredient is dip-extracted from the adventitious roots itself of ginseng while not losing an effective ingredient. | 2010-03-04 |
20100055213 | COMPOSITION COMPRISING THE EXTRACT OF CRUDE DRUG COMPLEX HAVING NEUROPROTECTIVE ACTIVITY FOR PREVENTING AND TREATING STROKE AND NEURODEGENERATIVE DISEASES - The present invention relates to a composition comprising an extract of crude drug complex comprising | 2010-03-04 |
20100055214 | METHOD FOR INCREASING BLOOD FLOW TO MAMMALIAN SKELETAL MUSCLE BY ADMINISTERING L-ARGNINE, CRATAEGUS EXTRACT, ARTICHOKE FLAVONOIDS AND GYMNOSTEMMA PENTAPHYLLUM EXTRACT - A nutritional composition and method is provided for increasing blood flow to skeletal muscle in an individual by supporting the biological activity of nitric oxide comprising therapeutically effective amounts of L-arginine, | 2010-03-04 |
20100055215 | PROCESS TO LOSE WEIGHT, DRAIN UNWANTED BODY FATS AND OTHER TOXINS - A method is disclosed comprising placing about thirty-two fluid ounces of water into a receptacle, placing the receptacle with water on a burner and bringing the water to a boil, ceasing to heat the water, adding about one tablespoonful or five grams of tea beverage flavorant to the water; and brewing the combination of the water and the tea beverage flavorant for about three to five minutes. The method may further include filtering out any solid tea in the combination of water and tea beverage flavorant, and consuming the combination of the water and the tea beverage flavorant. | 2010-03-04 |
20100055216 | Pharmaceutical composition for inhibiting the syndrome of snoring and preparation thereof - A method of treating a patient having snoring symptoms is disclosed, which includes administering to a patient in need thereof an effective amount of the pharmaceutical composition comprising | 2010-03-04 |
20100055217 | COSMETIC COMPOSITION COMPRISING A COMBINATION OF LIPOCHROMAN-6 AND AN EXTRACT OF LONGOZA, AND ITS USE - The invention relates to a cosmetic composition formulated for topical application to the skin, comprising as active agent a combination of lipochroman-6 and an extract of Longoza ( | 2010-03-04 |
20100055238 | MIXTURE OF LACTIC BACTERIA FOR THE PREPARATION OF GLUTEN FREE BAKED PRODUCTS - The present invention concerns a mixture of lactic bacteria for yeasting of gluten-free baked products. Particularly, the invention concerns the use of “natural yeast” based on selected lactic bacteria as yeasting agent for the production of gluten-free bread, with improved sensory and nutritional property, designed for celiac patients feeding. | 2010-03-04 |
20100055239 | EVAPORATOR OF VINASSE CONCENTRATION FOR DISTILLERIES IN GENERAL - “EVAPORATOR OF VINASSE CONCENTRATION FOR DISTILLERIES IN GENERAL”, it is applied preferentially in the distillery ( | 2010-03-04 |
20100055240 | METHOD FOR PRODUCING CHEESE - The present invention relates to a method of producing curd or cheese from a milk composition comprising the following steps: • adding to milk composition a protein hydrolysate, and/or a peptide and/or a mixture of peptides; • heat-treating the milk composition after that the protein hydrolysate is added; • coagulating the heat treated milk to form a gel; and • processing the formed gel into a cheese curd and separating the whey from the curd; and • optionally making cheese from the curd. | 2010-03-04 |
20100055241 | FENUGREEK SEED HAVING REDUCED BITTER TASTE AND METHOD FOR PRODUCING THE SAME - It is an object of the present invention to obtain fenugreek seeds having reduced bitter taste without causing significant changes in non-bitter components contained in fenugreek seeds. | 2010-03-04 |
20100055242 | METHOD FOR PREPARING SOFT VEGETABLE MATERIAL - The present invention provides a method for preparing a soft vegetable material which is suitably used for the production of a food or a meal for, in particular, the aged persons and which holds the shape of a particular ingredient of the food. The method comprises the steps of: (1) freezing a vegetable material and then thawing the frozen vegetable material to thus form a thawed vegetable material; (2) immersing the thawed vegetable material in a dispersion containing a pectin-decomposition enzyme or a cellulose-decomposition enzyme under reduced pressure; and (3) subjecting the vegetable material, which has been immersed in the dispersion and then thawed, to a heat-treatment at a temperature for a time sufficient for deactivating the pectin-decomposition enzyme or a cellulose-decomposition enzyme. Moreover, the thawing treatment in the foregoing step (1) may likewise be carried out simultaneous with the step of the enzyme-impregnation treatment under reduced pressure. | 2010-03-04 |
20100055243 | METHOD FOR PRODUCING LOW-CAFFEINE TEA EXTRACT - To provide a method for reducing a caffeine amount in a caffeine-containing tea extract liquid without deteriorating the original flavor of tea. The present invention provides a method for producing a low-caffeine tea extract, including the steps of: treating a caffeine-containing tea extract with tannase; causing a mixture of non-ester-type catechins and caffeine to be deposited in the caffeine-containing tea extract after the tannase treatment; and separating the deposited mixture for removal. Moreover, the present invention provides a low-caffeine tea extract obtained according to the production method and a food or drink containing the low-caffeine tea extract. | 2010-03-04 |
20100055244 | SPORE SURFACE DISPLAYS OF BIOACTIVE MOLECULES - This invention discloses novel bacterial spore systems. It has now been found surprisingly that under certain conditions bacterial spore systems can be used in the food and feed industry, preferably in animal feeding and as biohybrid material. More precisely applicant has found the following: Genetically modified or genetically engineered viable spore systems expressing bioactive polypeptides, for example bacteriocins and/or enzymatically active feed enzymes, at the spore surface, have a great potential use in animal feeding. Further, it has been found that genetically modified or “genetically engineered inert spore systems expressing affinity ligands or immobilized enzymes at the surface have a great potential use in biocatalysis and in the construction of biocatalytic films. Especially the resistance to harsh chemicals, desiccation, strong pressure, or high temperatures allows the spores to be a potentially valuable tool for the display of bioactive molecules, like biocatalytic enzymes or bioactive feed enzymes that must survive harsh conditions to deliver their full potential. Finally, applicant has found that instead of translational fusions to spore structural genes as it is known from the prior art described above, passenger bioactive polypeptides, as for example enzymes, bacteriocins, affinity ligands, can also be fused to spore-specific surface enzymes, for example to spore specific enzymes as mentioned herein above. | 2010-03-04 |
20100055245 | Modifying Flavor Experience Via Aroma Delivery - A method for modifying flavor experience via aroma delivery including applying at least one aroma on a comestible's packaging, the aroma causing the consumer to perceive a modified flavor of the comestible upon ingestion of the comestible. The comestible may be a beverage, such as a carbonated soft drink, fruit juice, water or grain-based beverage. | 2010-03-04 |
20100055246 | NUTRITION DELIVERY CAPSULES FOR FUNCTIONAL FOODS - Stabilized nanoparticulate nutritive compositions include nano-scale particles of at least one nutritive substance and molecules of at least one stabilizing agent that associate with the nutritive nanoparticles. Stabilized nanoparticulate nutritive compositions are prepared by suspending relatively larger particles of a nutritive substance in a solvent and breaking down the larger sized nutritive particles and associating the particles with the stabilizing agent. Stabilized nanoparticulate nutritive compositions can readily be combined with a variety of food media. | 2010-03-04 |
20100055247 | Nutritional Compositions for Athletes - Nutritional compositions in a dry powder, bar, and gel form including a 2:1 ratio of maltodextrin to fructose and one or more proteins. Further compositions include maltodextrin, fructose, whey protein, and a standardized amount of an extract selected from the group consisting of green tea, pomegranate, and mangosteen. Having the carbohydrates and one or more proteins present in a 12:1 ratio also has been found to be desirable. The addition of select vitamins and electrolytes further aid in carbohydrate metabolism and general hydration. | 2010-03-04 |